J&J Unit Under Scrutiny For Alleged Off-Label Marketing

Law360, New York (August 8, 2006, 12:00 AM EDT) -- Johnson & Johnson said in a U.S. Security and Exchange Commission filing Tuesday that one of its subsidiaries has received a subpoena related to the alleged off-label marketing of its epilepsy and migraine drug Topamax.

J&J said it was cooperating with the recent subpoena, which it received in June.

This is not the first time the company has come under fire for alleged off-label marketing of the drug.

In December 2003, J&J subsidiary Ortho-McNeil Pharmaceutical Inc. received its first subpoena from the U.S. Attorney’s Office for...
To view the full article, register now.